Geographic Atrophy

Riaz Qureshi, PhD, explains the effects of spin sneaking into systematic reviews and ways the scientific community can better identify it to improve the validity.

Researchers train deep learning model on OCT scans to ID patients eligible for GA trials.

Durga Borkar, MD, MMCi, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss Fas inhibition with ONL-1204 for the treatment of geographic atrophy: First-time results from a phase 1b study, which she is presenting at the ASRS meeting held in Stockholm, Sweden.

Rishi P. Singh, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Srinivas Sai Kondapalli, MD, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA.

Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the ASRS meeting held in Stockholm, Sweden.

Researchers from the UKB Eye Clinic, in cooperation with the University of Bonn and in close collaboration with basic and clinical scientists, have examined patients with early forms of AMD. The researchers focused on the so-called iRORA lesions, which are very early anatomical signs of retinal damage.

Comanagement is a key component for treatment of disease.

Durga Borkar, MD, MMCi, recently discussed the quality data (Qdata, Verana Health) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data.

Apellis plans to seek re-examination, with a final opinion expected in fourth quarter of 2024.

Repeated 0.1-ml intravireal injections of lampalizumab, antigen-binding fragment of a humanized monoclonal antibody that inhibits complement factor D, seem to be associated with a low risk of elevated IOP

During interview earlier this year, we asked leaders in the retina field would tell residents and medical students as they train for the next decades in retinal care. Here's what 2 of them had to say.

This PER On Air - Ophthalmology Times podcast examines the new treatment paradigm for patients with geographic atropy, following the introduction of complement-targeting therapies.

4D-175 will be evaluated in the GAZE clinical trial, an upcoming phase 1, open-label trial.

In this Ophthalmology Times EyePod podcast, Mandeep S. Singh, MD, PhD, speaks with Mark S. Humayun, MD, PhD, about the progress made by a team of USC researchers on a novel stem cell patch for treating advanced dry age-related macular degeneration.

How retina specialists are approaching treatment of GA in clinic.

The retrospective real-world evaluation of the drug considered several important as-yet-unanswered questions

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

The primary endpoint for the ReNEW and ReGAIN trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography (SD-OTC) and ellipsoid zone mapping at week 48.

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.

An ophthalmologist presents the case of a 76-year-old woman who has geographic atrophy and progressively worsening vision in her right eye, with a history of macular macrovessel and choroidal hemangioma.

Katherine Talcott, MD, presents the case of a 64-year-old woman with geographic atrophy and a family history of age-related macular degeneration.

The hypothesis is based on a post hoc analysis of data from 2 phase 3 clinical trials of pegcetacoplan by Dun Jack Fu, PhD, and colleagues.

Data can clear a path to trends and strategies to meet patients’ needs